Drug Type Small molecule drug |
Synonyms AM 10257 |
Target |
Action antagonists |
Mechanism CB2 antagonists(Cannabinoid CB2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Active Organization- |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H35N3O2 |
InChIKeyFMJXYCCDMAGPLE-UHFFFAOYSA-N |
CAS Registry2316841-32-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fibrosis | Preclinical | China | 01 Jan 2019 | |
| Fibrosis | Preclinical | China | 01 Jan 2019 | |
| Fibrosis | Preclinical | China | 01 Jan 2019 | |
| Inflammation | Preclinical | China | 01 Jan 2019 | |
| Inflammation | Preclinical | China | 01 Jan 2019 | |
| Inflammation | Preclinical | China | 01 Jan 2019 | |
| Neurodegenerative Diseases | Preclinical | China | 01 Jan 2019 | |
| Neurodegenerative Diseases | Preclinical | China | 01 Jan 2019 | |
| Neurodegenerative Diseases | Preclinical | China | 01 Jan 2019 |





